Minodronic acid
- Generic Name
- Minodronic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C9H12N2O7P2
- CAS Number
- 180064-38-4
- Unique Ingredient Identifier
- 40SGR63TGL
- Indication
Investigated for use/treatment in multiple myeloma, breast cancer, osteoporosis, and lung cancer.
Efficacy and Safety of Minodronate in Patients With Low Back Pain
Phase 4
Not yet recruiting
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT05645289
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis
Phase 3
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 330
- Registration Number
- NCT05305183
- Locations
- 🇨🇳
Shandong New Time Pharmaceutical Co., LTD, Shandong, China
Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 48
- Registration Number
- NCT02295436
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath